(Q38261236)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25327387%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

review article

1 reference

title

Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25327387%20AND%20SRC:MED&resulttype=core&format=json

metabolic dysfunction–associated steatotic liver disease

21 February 2020

main subject

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25327387%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Stefano Ballestri

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25327387%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

4

Paola Loria

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25327387%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

3

Giovanni Targher

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25327387%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

20 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25327387%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Gastroenterology & Hepatology

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25327387%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25327387%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25327387%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

629-650

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25327387%20AND%20SRC:MED&resulttype=core&format=json

Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

From NAFLD in clinical practice to answers from guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Long term prognosis of fatty liver: risk of chronic liver disease and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Long-term follow-up of patients with nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

The Framingham risk score and heart disease in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Prediction of first coronary events with the Framingham score: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

When to remeasure cardiovascular risk in untreated people at low and intermediate risk: observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Electron beam CT versus helical CT scans for assessing coronary calcification: current utility and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

n-6 Fatty acids and cardiovascular health: a review of the evidence for dietary intake recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

A lipidomic analysis of nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Dietary fructose in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Improving dietary patterns in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Consumption of cereal fiber, mixtures of whole grains and bran, and whole grains and risk reduction in type 2 diabetes, obesity, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Diet and exercise in management of obesity and overweight

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Alcohol consumption appears to protect against non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Effects of physical exercise on inflammatory markers of atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Irisin in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Integration of signals generated by nutrients, hormones, and exercise in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Pharmacological agents for NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

The role of medications for the management of patients with NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Antioxidant supplements to prevent mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Liver and diabetes. A vicious circle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Metformin and its clinical use: new insights for an old drug in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

The cardiovascular safety of incretin-based therapies: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

GLP-1 receptor agonists: a clinical perspective on cardiovascular effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Potential for statins in the chemoprevention and management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Statins and primary liver cancer: a meta-analysis of observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Chemopreventive strategies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Statins in liver disease: a molehill, an iceberg, or neither?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Fish oil -- how does it reduce plasma triglycerides?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

n-3 fatty acids in patients with multiple cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Polymorphism in the farnesyl diphosphate farnesyl transferase 1 gene and nonalcoholic fatty liver disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

The renin-angiotensin system: a link between obesity, inflammation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Safety and Effectiveness of the Intragastric Balloon for Obesity. A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Multi-centre European experience with intragastric balloon in overweight populations: 13 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

500 intragastric balloons: what happens 5 years thereafter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Five percent weight lost in the first month of intragastric balloon treatment may be a predictor for long-term weight maintenance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Bariatric surgery and cardiovascular outcomes: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Bariatric surgery and long-term cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Is mipomersen ready for clinical implementation? A transatlantic dilemma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Endocrine and liver interaction: the role of endocrine pathways in NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Nonalcoholic fatty liver disease and reduced serum vitamin D(3) levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

How different is the dietary pattern in non-alcoholic steatohepatitis patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143

The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2015.965143